Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bruker Makes Majority Investment in MIMETAS to Enhance Drug Discovery Efforts

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Source

Read at synbiobeta.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

Bruker has made a majority investment in MIMETAS to integrate advanced organ-on-a-chip human tissue models with Bruker’s molecular and cellular characterization technologies, aiming to accelerate drug discovery and development.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to link your drug discovery tools closely with human-relevant tissue models now that Bruker is backing integrated organ-on-a-chip platforms. This investment makes human tissue models a must-have component for competitive preclinical testing workflows.

◆ Coverage

1 source · 11 Aug 2026

◆ Related on Wire

◆ Topics

Biotechorgan-on-a-chipdrug-discoveryhuman-tissue-modelspharmaceutical-rdbiotech-investment